Αρχική World News Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial

Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial

Although mesothelioma typically develops in the lining surrounding the lungs—about 75% – 80% of the time—it is not actually a type of lung cancer. Instead, it is a rare cancer that may begin in the lining of different parts of the body, including the abdomen, heart, and testicles. It makes sense, then, that Mesothelioma Awareness Day would not take place during Lung Cancer Awareness Month in November, but rather have its own distinct date: September 26.

Mesothelioma Awareness Day was established by the Mesothelioma Applied Research Foundation in 2004 to bring attention and funding to mesothelioma. Although advances have been made, patients with mesothelioma still need better treatment options. Mesothelioma that begins in the lining of the lungs, also known as pleural mesothelioma, is a rare and aggressive form of cancer, with a five-year survival rate of less than 10%. However, researchers are working diligently to find new therapies for these patients.

In 2020, two clinical trials, one in the United States (PrE0505) and one in Australia (DREAM), demonstrated that the addition of a drug called durvalumab to standard chemotherapy improved outcomes for patients with pleural mesothelioma that could not be removed by surgery. Durvalumab is a type of immunotherapy known as a monoclonal antibody and it works by stimulating the immune system to destroy cancer cells. Durvalumab is already approved by the US Food and Drug Administration to treat certain types of lung cancer. Both trials showed that the combination treatment was well-tolerated with no unexpected side effects.

Now, researchers are building on this work with the PrE0506/DREAM3R clinical trial. This large trial will confirm if combination treatment with chemotherapy and durvalumab does in fact help patients live longer. Patients who participate in the study will receive either the usual treatment (chemotherapy consisting of pemetrexed and cisplatin or sometimes carboplatin) or the usual treatment plus durvalumab immunotherapy. Participants will be randomly assigned by a computer to one of the two groups, and there will be twice as many patients in the second group (usual treatment + durvalumab) as the first. Those in the second group will continue taking durvalumab following chemotherapy until their cancer begins to grow, they experience significant side effects, or they choose to stop taking part in the trial.

PrE0506/DREAM3R is currently enrolling patients in the United States, Australia, and New Zealand. PrECOG, LLC is sponsoring the DREAM3R study in the US, while The University of Sydney, through its NHMRC Clinical Trials Centre, is leading the trial in Australia and New Zealand in collaboration with the Thoracic Oncology Group of Australasia (TOGA). The lead researchers for the trial are Patrick M. Forde, MD (Johns Hopkins University) in the US and Anna Nowak, MD (The University of Western Australia) in Australia and New Zealand.

Learn more about PrE0506/DREAM3R in honor of Mesothelioma Awareness Day.


Katie Heller, MA, is a guest writer who works in marketing and clinical education at ECOG-ACRIN Cancer Research Group. Previously, she held roles at the American Society of Clinical Oncology and their foundation, Conquer Cancer. She has nearly a decade of experience in oncology and health care communications. Katie received a bachelor’s degree in English from Loyola University Maryland and a master’s degree in Media, Culture, and Communication from New York University.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Despite Proven Safety of HPV Vaccines, More Parents Have Concerns

October 22, 2021, by NCI Staff Credit: National Cancer Institute Despite more than 15 years of consistent evidence that HPV vaccines are safe and effective, a...

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy...

Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities

Suzette Simon lost her mother to breast cancer. In 2020, she learned that she had the disease, as well. Realizing how much harder breast...

Why Wearing Comfortable Clothes During Cancer Treatment Matters

Voices on Cancer is an award-winning Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. Cindy Trice is...

Breast cancer surgery: ‘I’m proud of the tattoos inked across my chest’

Wendy had a double mastectomy in 2017 and remained flat. “When the consultant told me, I remember crying and saying that I have 2 young...

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of...